



**REGIONAL DRUG AND THERAPEUTICS CENTRE  
(NEWCASTLE)**

# **COST COMPARISON CHARTS**

## **April 2018**

**16/17 Framlington Place  
Newcastle upon Tyne  
NE2 4AB**

### **INTRODUCTION**

Charts are organised by BNF classification and show comparative costs at basic NHS prices (as of April 2018) for selected agents. Except where indicated otherwise, each chart shows the cost of 1 year<sup>1</sup> of treatment at a standard daily dose (shown in brackets). The doses given are not intended to imply therapeutic equivalence and for some drug groups – such as ACE inhibitors – doses may vary according to indication. Additionally, in some therapeutic areas – such as antibacterial drugs – the duration of treatment may differ from that shown.

The cost comparison charts are also available in Excel format to all stakeholders (under password protection) on our NHS website: <http://rdtc.nhs.uk/>

The contents table on the following page has been formatted so that you can quickly navigate to specific charts by holding the cursor over the chart title and clicking your left mouse button whilst holding down the “Ctrl” key.

**NOT TO BE USED FOR COMMERCIAL OR MARKETING PURPOSES**

---

<sup>1</sup> 1 year in this case is equal to 364 days rather than 365 when 1 month equals 28 days.


To navigate to the chart required, hover the cursor over the section required, press CTRL and click with the left mouse button.

<b>CONTENTS by BNF 74 classification</b>	<b>Page</b>
1.1.1 Dyspepsia and gastro-oesophageal reflux disease.....	5
1.2 Antispasmodics and other drugs altering gut motility .....	5
1.3 Antisecretory drugs and mucosal protectants .....	6
1.4 Acute diarrhoea.....	7
Chronic diarrhoea .....	7
1.5.1 Aminosalicylates .....	8
1.5.2 Rectal foams .....	9
1.6 Laxatives .....	10
2.2 Diuretics .....	11
2.4 Beta-adrenoceptor blocking drugs.....	12
2.5.4 Alpha-adrenoceptor blocking drugs .....	12
2.5.5 Drugs affecting the renin-angiotensin system .....	13
2.6.1/2.6.3 Nitrates and other antianginal drugs.....	14
2.6.2 Calcium-channel blockers.....	15
2.8 Anticoagulants .....	16
2.9 Antiplatelet drugs .....	17
2.12 Lipid-regulating drugs .....	18
3.1 Bronchodilators .....	19
3.2 Corticosteroids .....	20
3.2 Corticosteroid & Bronchodilator Inhalers .....	21
3.1 & 3.2 Inhaled therapy licensed for COPD.....	22
3.3 Cromoglicate & related therapy, leukotriene receptor antagonists, and phosphodiesterase type-4 inhibitors.....	23
3.4.1 Antihistamines.....	23
4.1 Hypnotics & anxiolytics .....	24
4.2 Atypical antipsychotics – maintenance doses (adults with psychosis).....	25
4.2 Atypical antipsychotics – Low doses .....	26
4.3 Antidepressant drugs.....	27
4.4 CNS stimulants and drugs used for attention deficit hyperactivity disorder - Stimulant .....	28
4.4 CNS stimulants and drugs used for attention deficit hyperactivity disorder – Stimulant - Methylphenidate MR only .....	29
4.4 CNS stimulants and drugs used for attention deficit hyperactivity disorder – Non-Stimulant.....	30
4.6 Drugs used in nausea and vertigo .....	30
4.7 Analgesics.....	31
4.7.2 Opioid analgesics.....	32
4.7.2 Opioid analgesics – patches only .....	33
4.7.2 MR Opioid analgesics .....	34


4.7.2 Strong opioid analgesics – equipotent dose cost per 24 hours .....	35
4.7.3 Neuropathic pain.....	36
4.7.4.1 Antimigraine drugs (acute).....	36
4.8 Antiepileptic drugs.....	37
4.9 Drugs used in parkinsonism and related disorders - Dopamine-receptor agonists.....	38
4.9 Drugs used in parkinsonism and related disorders - Levodopa, COMT and MAO-B inhibitors .....	39
4.10.2 Nicotine dependence .....	40
4.11 Drugs for dementia .....	41
5 Miscellaneous antimicrobial and anthelmintic drugs .....	42
5.1.1 Penicillins .....	42
5.1.2 Cephalosporins .....	43
5.1.3 Tetracyclines.....	43
5.1.12 Quinolones.....	44
5.2 Miscellaneous antifungal drugs (including topical and gynaecological) .....	44
6.1.1 Insulins (prefilled pens and cartridges) .....	45
Needles For Pre-Filled And Reusable Insulin Pens .....	46
Blood lancets .....	47
6.1.6 Blood glucose monitoring .....	48
6.1.2 Antidiabetic drugs .....	49
6.1.2 Antidiabetic drugs – Newer agents.....	50
6.4.1 Female sex hormones and their modulators – combination hrt preparations .....	51
6.4.1 Female sex hormones and their modulators – oestrogen only hrt patches.....	52
6.4.1 Female sex hormones and their modulators – oestrogen only hrt options.....	53
6.6.2 Bisphosphonates and other drugs affecting bone metabolism.....	54
7.3 Contraceptives – combined hormonal contraceptives.....	55
7.3 Contraceptives – Progestogen-only contraceptives .....	56
7.4.1 Drugs for urinary retention .....	57
7.4.2 Drugs for urinary frequency, enuresis and incontinence .....	58
7.4.5 Drugs for erectile dysfunction .....	59
8.3.4.2 Prostate cancer.....	59
9.6.4 Calcium and vitamin D.....	60
9.6.4 Vitamin D preparations - prevention .....	60
9.6.4 Vitamin D preparations – treatment.....	61
10.1.1 Non-steroidal anti-inflammatory drugs.....	62
10.3.2 Rubefacients, topical NSAIDs, capsaicin, and poultices .....	63
11.4.2 Other anti-Inflammatory preparations.....	63
11.6 Treatment of Glaucoma .....	64
11.8.1 Tear Deficiency, Ocular Lubricants, and Astringents .....	65
12.2.1 Nasal steroids .....	65

13.2.1 Emollients (by volume) .....	66
13.2.1 Emollients per 100g/ml .....	67
13.2.1.1 Emollient bath and shower preparations per 100g/ml .....	68
13.4 Topical Corticosteroids .....	69
13.4 Topical Corticosteroids with antimicrobial .....	70
Topical scalp preparations/Shampoos for eczema and psoriasis .....	70
13.5.2 Steroid and vitamin D topical preparations .....	71
13.6.1 Topical preparations for acne .....	71
Stoma adhesive removers .....	72
Patent expiry table April 2018 to March 2019.....	73

### 1.1.1 Dyspepsia and gastro-oesophageal reflux disease




### 1.2 Antispasmodics and other drugs altering gut motility




[Contents](#)


## 1.3 Antisecretory drugs and mucosal protectants


[Contents](#)

1.4 Acute diarrhoea




Chronic diarrhoea



[Contents](#)


## 1.5.1 Aminosalicylates



[Contents](#)




1.5.2 Rectal foams




[Contents](#)

## 1.6 Laxatives




[Contents](#)


## 2.2 Diuretics


[Contents](#)

### 2.4 Beta-adrenoceptor blocking drugs




### 2.5.4 Alpha-adrenoceptor blocking drugs




[Contents](#)

## 2.5.5 Drugs affecting the renin-angiotensin system




[Contents](#)

## 2.6.1/2.6.3 Nitrates and other antianginal drugs




[Contents](#)

## 2.6.2 Calcium-channel blockers



[Contents](#)


2.8 Anticoagulants



[Contents](#)




## 2.9 Antiplatelet drugs




[Contents](#)


## 2.12 Lipid-regulating drugs

[Contents](#)

## 3.1 Bronchodilators


[Contents](#)

### 3.2 Corticosteroids



[Contents](#)

3.2 Corticosteroid & Bronchodilator Inhalers



High dose ICS in adult  
High dose therapy stage - only after referring to secondary care

Medium dose ICS in adult  
Additional add-on therapy stage


Low dose ICS in adult  
Regular Preventer or inhaler add-on therapy stage

Low dose LABA - 12mcg formoterol


Low dose LABA - 12mcg formoterol

[Contents](#)


## 3.1 &amp; 3.2 Inhaled therapy licensed for COPD

[Contents](#)

### 3.3 Cromoglicate & related therapy, leukotriene receptor antagonists, and phosphodiesterase type-4 inhibitors




### 3.4.1 Antihistamines



[Contents](#)


## 4.1 Hypnotics &amp; anxiolytics



[Contents](#)




4.2 Atypical antipsychotics – maintenance doses (adults with psychosis)




[Contents](#)

## 4.2 Atypical antipsychotics – Low doses




[Contents](#)

## 4.3 Antidepressant drugs




[Contents](#)

#### 4.4 CNS stimulants and drugs used for attention deficit hyperactivity disorder - Stimulant




[Contents](#)

**4.4 CNS stimulants and drugs used for attention deficit hyperactivity disorder – Stimulant - Methylphenidate MR only**




### 4.4 CNS stimulants and drugs used for attention deficit hyperactivity disorder – Non-Stimulant




[Contents](#)

### 4.6 Drugs used in nausea and vertigo




[Contents](#)

## 4.7 Analgesics



[Contents](#)

## 4.7.2 Opioid analgesics


[Contents](#)




4.7.2 Opioid analgesics – patches only



[Contents](#)


4.7.2 MR Opioid analgesics



Several NHS bodies recommend that modified-release forms of strong opioids be prescribed by brand name to avoid confusion and reduce risk of harm.


[Contents](#)

### 4.7.2 Strong opioid analgesics – equipotent dose cost per 24 hours




[Contents](#)

### 4.7.3 Neuropathic pain




[Contents](#)

### 4.7.4.1 Antimigraine drugs (acute)




[Contents](#)

### 4.8 Antiepileptic drugs




[Contents](#)

4.9 Drugs used in parkinsonism and related disorders - Dopamine-receptor agonists




#### 4.9 Drugs used in parkinsonism and related disorders - Levodopa, COMT and MAO-B inhibitors



[Contents](#)


## 4.10.2 Nicotine dependence



[Contents](#)




## 4.11 Drugs for dementia




[Contents](#)

### 5 Miscellaneous antimicrobial and anthelmintic drugs




#### 5.1.1 Penicillins




[Contents](#)

### 5.1.2 Cephalosporins




### 5.1.3 Tetracyclines




[Contents](#)

## 5.1.12 Quinolones




## 5.2 Miscellaneous antifungal drugs (including topical and gynaecological)




[Contents](#)

### 6.1.1 Insulins (prefilled pens and cartridges)




[Contents](#)




[Contents](#)

**Needles For Pre-Filled And Reusable Insulin Pens**




[Contents](#)

**Blood lancets**



[Contents](#)


6.1.6 Blood glucose monitoring



[Contents](#)




6.1.2 Antidiabetic drugs




[Contents](#)

6.1.2 Antidiabetic drugs – Newer agents




[Contents](#)

**6.4.1 Female sex hormones and their modulators – Combination HRT preparations**




[Contents](#)

**6.4.1 Female sex hormones and their modulators – Oestrogen only HRT patches**




**6.4.1 Female sex hormones and their modulators – Oestrogen only HRT options**




[Contents](#)

### 6.6.2 Bisphosphonates and other drugs affecting bone metabolism



[Contents](#)


7.3 Contraceptives – combined hormonal contraceptives



[Contents](#)

For a more detailed comparison of contraceptives, access the excel version of the cost comparison charts via the RDTC website (link available via the title page). This is available to stakeholders only under password protection

7.3 Contraceptives – Progestogen-only contraceptives




[Contents](#)

For a more detailed comparison of contraceptives, access the excel version of the cost comparison charts via the RDTC website (link available via the title page). This is available to stakeholders only under password protection




## 7.4.1 Drugs for urinary retention




[Contents](#)


## 7.4.2 Drugs for urinary frequency, enuresis and incontinence


[Contents](#)

### 7.4.5 Drugs for erectile dysfunction




### 8.3.4.2 Prostate cancer




[Contents](#)

### 9.6.4 Calcium and vitamin D




### 9.6.4 Vitamin D preparations - prevention




[Contents](#)

### 9.6.4 Vitamin D preparations – treatment




[Contents](#)

10.1.1 Non-steroidal anti-inflammatory drugs




[Contents](#)

### 10.3.2 Rubefacients, topical NSAIDs, capsaicin, and poultices




### 11.4.2 Other anti-Inflammatory preparations



[Contents](#)


11.6 Treatment of Glaucoma



[Contents](#)




### 11.8.1 Tear Deficiency, Ocular Lubricants, and Astringents




[Contents](#)

### 12.2.1 Nasal steroids




[Contents](#)

13.2.1 Emollients (by volume)




[Contents](#)

13.2.1 Emollients per 100g/ml




[Contents](#)

## 13.2.1.1 Emollient bath and shower preparations per 100g/ml




[Contents](#)

### 13.4 Topical Corticosteroids




[Contents](#)

### 13.4 Topical Corticosteroids with antimicrobial




### Topical scalp preparations/Shampoos for eczema and psoriasis




[Contents](#)


### 13.5.2 Steroid and vitamin D topical preparations



### 13.6.1 Topical preparations for acne



[Contents](#)

**Stoma adhesive removers**[Contents](#)



**Patent expiry table April 2018 to March 2019**

Expiry dates below take account of the SPC and any paediatric extension. The table also indicates where a licence for a generic/biosimilar product is in the latter stages of the EU licensing process or is already available in the EU. However, it does not follow that a generic/biosimilar product will be available in the UK as patent issues differ between countries. Patent legislation is complex and the information below should be used as a guide only.

Note that patent expiries are subject to change when new licence extensions (SPC or paediatric) are granted to the originator product or if court decisions alter the patent status of a drug. In addition, the patent expiries detailed only cover the basic, manufacturing patent. Additional patents on formulations and uses can influence when a generic or biosimilar becomes available commercially.

Patent expiry date may not give an accurate date as to when a generic version will actually be marketed in the UK, once a generic has been granted a product licence.

Drug	BNF	Patent expiry date * = UK patent only, no SPC	Date includes paediatric extension	Generic or biosimilar available/ in development	Commissioning route
Enfuvirtide	5	2018 Apr			NHS England
Ezetimibe	2	2018 Apr	Yes	Yes	CCG
Ciclesonide ( <i>aerosol formulation</i> )	3	2018 May			
Ganirelix	6	2018 Jun*			
Varicela-zoster vaccine	14	2018 Jul			CCG
Tenofovir + enfavirenz + emtricitabine	5	2018 Aug		Yes	
Human papilloma virus vaccine (Cervarix®)	14	2018 Sep			CCG
Adalimumab	1; 10	2018 Oct	Yes	Yes	Depends on indication
Vardenafil HCl	7	2018 Oct *			CCG
Capsaicin ( <i>transdermal patch</i> )	4	2018 Dec			
Oxycodone + naloxone	4	2018 Dec*			CCG
Everolimus	8	2019 Jan	Yes	Yes	NHS England
Darunavir	5	2019 Feb	Yes	Yes	
Thalidomide (for angiogenesis)	8	2019 Feb			
Dexmedetomidine	15	2019 Mar*			CCG
Efalizumab	13	2019 Mar			
Gefitinib	8	2019 Mar			

<b>Drug</b>	<b>BNF</b>	<b>Patent expiry date * = UK patent only, no SPC</b>	<b>Date includes paediatric extension</b>	<b>Generic or biosimilar available/ in development</b>	<b>Commissioning route</b>
Iron isomaltoside 1000	9	2019 Mar			
Lanthanum carbonate	9	2019 Mar			CCG